BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pfeiffer P, Nielsen D, Bjerregaard J, Qvortrup C, Yilmaz M, Jensen B. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Annals of Oncology 2008;19:1141-5. [DOI: 10.1093/annonc/mdn020] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Power DG, Shah MA, Asmis TR., Garcia JJ., Kemeny NE. Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience. Invest New Drugs 2010;28:353-60. [DOI: 10.1007/s10637-009-9268-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
2 Eriksen JG, Kaalund I, Clemmensen O, Overgaard J, Pfeiffer P. Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash. Support Care Cancer 2017;25:2179-85. [DOI: 10.1007/s00520-017-3623-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
3 Yen C, Tsou H, Hsieh C, Chu C, Chiu C, Chen C, Tsao C, Tsai K, Tsai S, Chang J, Chang K. Sequential therapy of neoadjuvant biochemotherapy with cetuximab, paclitaxel, and cisplatin followed by cetuximab‐based concurrent bioradiotherapy in high‐risk locally advanced oral squamous cell carcinoma: Final analysis of a phase 2 clinical trial. Head & Neck 2019;41:1703-12. [DOI: 10.1002/hed.25640] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
4 Fernandez-Plana J, Pericay C, Quintero G, Alonso V, Salud A, Mendez M, Salgado M, Saigi E, Cirera L; ACROSS Study Group. Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study). BMC Cancer 2014;14:865. [PMID: 25417182 DOI: 10.1186/1471-2407-14-865] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
5 Guigay J, Le Caer H, Ortholan C, Aupérin A, Michel C, Mertens C. Treatment of inoperable elderly head and neck cancer patients. Curr Opin Oncol 2019;31:152-9. [PMID: 30985496 DOI: 10.1097/CCO.0000000000000526] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
6 Bailey CH, Jameson G, Sima C, Fleck S, White E, Von Hoff DD, Weiss GJ. Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials. J Cancer 2012;3:7-13. [PMID: 22211140 DOI: 10.7150/jca.3.7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
7 Shitara K, Ura T, Matsuo K, Takahari D, Yokota T, Yuki S, Yoshida M, Utsunomiya S, Sato Y, Yamaura H, Kato M, Inaba Y, Tajika M, Kawai H, Yamazaki K, Komatsu Y, Muro K. Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer. Eur J Cancer 2011;47:2673-80. [PMID: 21652203 DOI: 10.1016/j.ejca.2011.05.015] [Reference Citation Analysis]
8 Haraldsdottir S, Bekaii-Saab T. Integrating anti-EGFR therapies in metastatic colorectal cancer. J Gastrointest Oncol. 2013;4:285-298. [PMID: 23997940 DOI: 10.3978/j.issn.2078-6891.2013.028] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
9 Hashemkhani M, Demirci G, Bayir A, Muti A, Sennaroglu A, Mohammad Hadi L, Yaghini E, Loizidou M, MacRobert AJ, Yagci Acar H. Cetuximab-Ag2S quantum dots for fluorescence imaging and highly effective combination of ALA-based photodynamic/chemo-therapy of colorectal cancer cells. Nanoscale 2021;13:14879-99. [PMID: 34533177 DOI: 10.1039/d1nr03507j] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Goffin JR, Zbuk K. Epidermal growth factor receptor: pathway, therapies, and pipeline. Clin Ther 2013;35:1282-303. [PMID: 24054705 DOI: 10.1016/j.clinthera.2013.08.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 6.9] [Reference Citation Analysis]
11 Jensen BV, Schou JV, Yilmaz M, Johannesen HH, Skougaard K, Linnemann D, Hogdall EV, Larsen FO, Johansen JS, Pfeiffer P, Nielsen DL. Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status. Int J Cancer 2020. [PMID: 33336394 DOI: 10.1002/ijc.33448] [Reference Citation Analysis]
12 Loupakis F, Antoniotti C, Cremolini C, Zhang W, Yang D, Wakatsuki T, Bohanes P, Schirripa M, Salvatore L, Masi G, Ricci V, Graziano F, Ruzzo A, Benhaim L, Marmorino F, Ning Y, El-khoueiry R, Falcone A, Lenz H. Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients. Pharmacogenomics J 2014;14:322-7. [DOI: 10.1038/tpj.2014.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
13 Kang MJ, Hong YS, Kim KP, Kim SY, Baek JY, Ryu MH, Lee JL, Chang HM, Kim MJ, Chang HJ. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status. Invest New Drugs. 2012;30:1607-1613. [PMID: 21706149 DOI: 10.1007/s10637-011-9703-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
14 Yang Q, Huang Y, Jiang Z, Wang H, Li W, Zhang B, Xie D. Rechallenge of oxaliplatin-containing regimens in the third- or later-line therapy for patients with heavily treated metastatic colorectal cancer. Onco Targets Ther 2018;11:2467-73. [PMID: 29760556 DOI: 10.2147/OTT.S154220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Shitara K, Yokota T, Takahari D, Shibata T, Ura T, Komatsu Y, Yuki S, Yoshida M, Takiuchi H, Utsunomiya S, Yatabe Y, Muro K. Phase II Study of Combination Chemotherapy with Biweekly Cetuximab and Irinotecan for Pre-treated Metastatic Colorectal Cancer Harboring Wild-type KRAS. Japanese Journal of Clinical Oncology 2010;40:699-701. [DOI: 10.1093/jjco/hyq026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
16 Schønnemann KR, Yilmaz M, Bjerregaard JK, Nielsen KM, Pfeiffer P. Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer. Eur J Cancer. 2012;48:510-517. [PMID: 22244801 DOI: 10.1016/j.ejca.2011.12.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
17 Kienle DL, Dietrich D, Ribi K, Wicki A, Quagliata L, Winterhalder RC, Koeberle D, Horber D, Bastian S, Kueng M, Saletti P, Helbling D, Baertschi D, Lugli A, Bernhard J, Andrieu C, von Moos R. Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10. Journal of Geriatric Oncology 2019;10:304-10. [DOI: 10.1016/j.jgo.2018.11.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
18 Chapman SJ, McKavanagh D, Burge ME, McPherson I, Walpole E, Hollingworth SA. Effectiveness of bevacizumab and cetuximab in metastatic colorectal cancer across selected public hospitals in Queensland. Asia Pac J Clin Oncol 2017;13:e253-61. [PMID: 27435535 DOI: 10.1111/ajco.12518] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Kennecke H, Chen L, Blanke CD, Cheung WY, Schaff K, Speers C. Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal cancer. Curr Oncol 2013;20:326-32. [PMID: 24311948 DOI: 10.3747/co.20.1600] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
20 Cersosimo RJ. Management of advanced colorectal cancer, Part 2. Am J Health Syst Pharm. 2013;70:491-506. [PMID: 23456402 DOI: 10.2146/ajhp110532b] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
21 Mennini FS, Marcellusi A, Fabiano G, Platini F, Bossi P. Rationale and budget impact of bimonthly use of Cetuximab in patients with recurrent and/or metastatic head and neck cancer. Head Neck 2019;41:908-14. [PMID: 30680828 DOI: 10.1002/hed.25481] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Sameen S, Barbuti R, Milazzo P, Cerone A, Del Re M, Danesi R. Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer. J Theor Biol 2016;389:263-73. [PMID: 26551156 DOI: 10.1016/j.jtbi.2015.10.019] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
23 Brodowicz T, Ciuleanu T, Radosavljevic D, Shacham-shmueli E, Vrbanec D, Plate S, Mrsic-krmpotic Z, Dank M, Purkalne G, Messinger D, Zielinski C. FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study. Annals of Oncology 2013;24:1769-77. [DOI: 10.1093/annonc/mdt116] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
24 Cripps C, Gill S, Ahmed S, Colwell B, Dowden S, Kennecke H, Maroun J, Samson B, Thirlwell M, Wong R. Consensus recommendations for the use of anti-egfr therapies in metastatic colorectal cancer. Curr Oncol 2010;17:39-45. [PMID: 21151408 DOI: 10.3747/co.v17i6.670] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
25 Bachet JB, Peuvrel L, Bachmeyer C, Reguiai Z, Gourraud PA, Bouché O, Ychou M, Bensadoun RJ, Dreno B, André T. Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review. Oncologist 2012;17:555-68. [PMID: 22426526 DOI: 10.1634/theoncologist.2011-0365] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
26 Larsen FO, Pfeiffer P, Nielsen D, Skougaard K, Qvortrup C, Vistisen K, Fromm AL, Jørgensen TL, Bjerregaard JK, Hoegdall E, Jensen BV. Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer. Acta Oncol 2011;50:574-7. [PMID: 21529301 DOI: 10.3109/0284186X.2010.546369] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
27 Heigener DF, Pereira JR, Felip E, Mazal J, Manzyuk L, Tan EH, Merimsky O, Sarholz B, Esser R, Gatzemeier U. Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial. Targ Oncol 2015;10:255-65. [DOI: 10.1007/s11523-014-0336-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
28 Garrett CR, Eng C. Cetuximab in the treatment of patients with colorectal cancer. Expert Opin Biol Ther 2011;11:937-49. [PMID: 21557708 DOI: 10.1517/14712598.2011.582464] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
29 Gerber DE, Choy H. Cetuximab in combination therapy: from bench to clinic. Cancer Metastasis Rev. 2010;29:171-180. [PMID: 20140759 DOI: 10.1007/s10555-010-9215-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
30 Nishiofuku H, Tanaka T, Aramaki T, Boku N, Inaba Y, Sato Y, Matsuoka M, Otsuji T, Arai Y, Kichikawa K. Hepatic arterial infusion of 5-fluorouracil for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy: a multicenter, retrospective analysis. Clin Colorectal Cancer. 2010;9:305-310. [PMID: 21208845 DOI: 10.3816/ccc.2010.n.044] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
31 Gaulin J, Kotb R, Turcotte E, Berard G, Sawan B, Schmutz G, Beauregard P. Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer. Curr Oncol 2009;16:84-6. [PMID: 19862366 DOI: 10.3747/co.v16i5.395] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
32 Tabernero J, Ciardiello F, Rivera F, Rodriguez-braun E, Ramos F, Martinelli E, Vega-villegas M, Roselló S, Liebscher S, Kisker O, Macarulla T, Baselga J, Cervantes A. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. Annals of Oncology 2010;21:1537-45. [DOI: 10.1093/annonc/mdp549] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 4.8] [Reference Citation Analysis]
33 Osumi H, Shinozaki E, Mashima T, Wakatsuki T, Suenaga M, Ichimura T, Ogura M, Ota Y, Nakayama I, Takahari D, Chin K, Miki Y, Yamaguchi K. Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer. Cancer Sci 2018;109:2567-75. [PMID: 29908105 DOI: 10.1111/cas.13698] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
34 Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin 2012;62:309-35. [PMID: 22576456 DOI: 10.3322/caac.20132] [Cited by in Crossref: 255] [Cited by in F6Publishing: 233] [Article Influence: 25.5] [Reference Citation Analysis]
35 Ostenfeld EB, Erichsen R, Iversen LH, Gandrup P, Nørgaard M, Jacobsen J. Survival of patients with colon and rectal cancer in central and northern Denmark, 1998-2009. Clin Epidemiol 2011;3 Suppl 1:27-34. [PMID: 21814467 DOI: 10.2147/CLEP.S20617] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
36 Fakih M, Wong R. Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer. Curr Oncol 2010;17 Suppl 1:S3-17. [PMID: 20680105 DOI: 10.3747/co.v17is1.616] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
37 Rohrer CL, Grullon Z, George SK, Castillo R, Karasiewicz K. A case of aseptic meningitis in a cetuximab-experienced patient with metastatic colon cancer. J Oncol Pharm Pract 2018;24:632-3. [PMID: 29157147 DOI: 10.1177/1078155217739685] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
38 Schoennemann KR, Bjerregaard JK, Hansen TP, De Stricker K, Gjerstorff MF, Jensen HA, Vestermark LW, Pfeiffer P. Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum. Gastric Cancer. 2011;14:219-225. [PMID: 21409520 DOI: 10.1007/s10120-011-0031-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
39 Personeni N, Rimassa L, Verusio C, Barni S, Rubino L, Bozzarelli S, Villa E, Carnaghi C, Tronconi MC, Gerardi C, Galli F, Floriani I, Destro A, Raschioni C, Labianca R, Santoro A. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study. Clin Colorectal Cancer 2015;14:162-9. [PMID: 25861836 DOI: 10.1016/j.clcc.2015.02.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
40 Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou AM, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz S. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov. 2016;6:1352-1365. [PMID: 27729313 DOI: 10.1158/2159-8290.cd-16-0050] [Cited by in Crossref: 129] [Cited by in F6Publishing: 82] [Article Influence: 21.5] [Reference Citation Analysis]
41 Qvortrup C, Jensen BV, Jorgensen TL, Nielsen D, Bjerregaard JK, Pfeiffer P. Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer. Acta Oncologica 2010;49:833-6. [DOI: 10.3109/0284186x.2010.482104] [Cited by in Crossref: 9] [Article Influence: 0.8] [Reference Citation Analysis]
42 Kasper S, Foch C, Messinger D, Esser R, Lamy FX, Rothe V, Chen W, Cheng AL, Rouyer M, Brodowicz T, Zielinski C. Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer. Eur J Cancer 2021;144:291-301. [PMID: 33383349 DOI: 10.1016/j.ejca.2020.11.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
43 Pfeiffer P, Sorbye H, Qvortrup C, Karlberg M, Kersten C, Vistisen K, Lindh B, Bjerregaard JK, Glimelius B. Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group. Clin Colorectal Cancer 2015;14:170-6. [PMID: 25956187 DOI: 10.1016/j.clcc.2015.03.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
44 Eng C, Bessudo A, Hart LL, Severtsev A, Gladkov O, Müller L, Kopp MV, Vladimirov V, Langdon R, Kotiv B, Barni S, Hsu C, Bolotin E, von Roemeling R, Schwartz B, Bendell JC. A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy. Int J Cancer 2016;139:177-86. [PMID: 26891420 DOI: 10.1002/ijc.30049] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
45 Abdelwahab S, Azmy A, Abdel-aziz H, Salim H, Mahmoud A. Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC). J Cancer Res Clin Oncol 2012;138:1487-92. [DOI: 10.1007/s00432-012-1229-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
46 Shitara K, Yuki S, Yoshida M, Takahari D, Utsunomiya S, Yokota T, Sato Y, Inaba Y, Tajika M, Kawai H, Yamaura H, Kato M, Yamazaki K, Komatsu Y, Muro K. Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. Invest New Drugs 2012;30:787-93. [DOI: 10.1007/s10637-010-9615-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
47 Mennini FS, Marcellusi A, Fabiano G, Rimassa L, Santoro A, Personeni N. Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer. Future Oncol 2019;15:2107-12. [PMID: 31161795 DOI: 10.2217/fon-2018-0904] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
48 Lamy FX, Batech M, Boutmy E, Ronga P, Salim S, Pescott CP. Comparative effectiveness of weekly versus every-2-weeks cetuximab in metastatic colorectal cancer in a US-insured population. J Comp Eff Res 2020;9:1117-29. [PMID: 33118841 DOI: 10.2217/cer-2020-0132] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Martín-Martorell P, Roselló S, Rodríguez-Braun E, Chirivella I, Bosch A, Cervantes A. Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. Br J Cancer. 2008;99:455-458. [PMID: 18665167 DOI: 10.1038/sj.bjc.6604530] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
50 You B, Chen EX. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab. J Clin Pharmacol 2012;52:128-55. [PMID: 21427284 DOI: 10.1177/0091270010395940] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
51 Siena S, Glynne-Jones R, Adenis A, Thaler J, Preusser P, Aguilar EA, Aapro MS, Loos AH, Esser R, Wilke H. Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication. Cancer. 2010;116:1827-1837. [PMID: 20143444 DOI: 10.1002/cncr.24945] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
52 Gomez D, De Rosa A, Addison A, Brooks A, Malik HZ, Cameron IC. Cetuximab therapy in the treatment of metastatic colorectal cancer: the future frontier? Int J Surg. 2013;11:507-513. [PMID: 23660586 DOI: 10.1016/j.ijsu.2013.04.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
53 Bossi P, Kornek G, Lanzetta G, Rozzi A, Füreder T, Locati L, Licitra L. Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer. Head Neck 2013;35:1471-4. [PMID: 23042567 DOI: 10.1002/hed.23170] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
54 Lévi F, Karaboué A, Gorden L, Innominato PF, Saffroy R, Giacchetti S, Hauteville D, Guettier C, Adam R, Bouchahda M. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. Cancer Chemother Pharmacol 2011;67:339-48. [PMID: 20401611 DOI: 10.1007/s00280-010-1327-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
55 Tapia Rico G, Townsend AR, Broadbridge V, Price TJ. Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence. Drugs Aging 2017;34:173-89. [PMID: 28197947 DOI: 10.1007/s40266-017-0439-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
56 Sotelo Lezama MJ, Sastre Valera J, Díaz-Rubio García E. Impact of cetuximab in current treatment of metastatic colorectal cancer. Expert Opin Biol Ther 2014;14:387-99. [PMID: 24479733 DOI: 10.1517/14712598.2014.883376] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
57 Peyrade F, Cupissol D, Geoffrois L, Rolland F, Borel C, Ciais C, Faivre S, Guigay J. Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: review of the literature and proposal for management changes. Oral Oncol 2013;49:482-91. [PMID: 23415727 DOI: 10.1016/j.oraloncology.2013.01.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
58 Carneiro BA, Ramanathan RK, Fakih MG, Krishnamurthi SS, Lembersky BC, Stoller RG, Lancaster SL, Pinkerton RA, Crandall TL, Schmotzer AR, Potter DM, Bahary N. Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer. Clin Colorectal Cancer 2012;11:53-9. [PMID: 21813336 DOI: 10.1016/j.clcc.2011.05.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
59 Nielsen DL, Palshof JA, Larsen FO, Jensen BV, Pfeiffer P. A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy. Cancer Treat Rev. 2014;40:701-715. [PMID: 24731471 DOI: 10.1016/j.ctrv.2014.02.006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
60 Macarulla T, Ramos FJ, Elez E, Capdevila J, Peralta S, Tabernero J. Update on novel strategies to optimize cetuximab therapy in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2008;7:300-8. [PMID: 18794061 DOI: 10.3816/CCC.2008.n.039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
61 Temraz S, Mukherji D, Alameddine R, Shamseddine A. Methods of overcoming treatment resistance in colorectal cancer. Crit Rev Oncol Hematol 2014;89:217-30. [PMID: 24075059 DOI: 10.1016/j.critrevonc.2013.08.015] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]